Evidence map›Paper›PMID 35328641›Full record

ArticleInternational journal of molecular sciences2022

Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics.

Alex Gomez-Gomez, Paula Aguilera, Klaus Langohr, Gregori Casals, Cristina Pavon, Josep Marcos, Jordi To-Figueras, Oscar J Pozo

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. More than a ring: the emerging role of heme in angiogenesis.Cell communication and signaling : CCS · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Endothelial Dysfunction in Acute Hepatic Porphyrias.Diagnostics (Basel, Switzerland) · 2022
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Alex Gomez-GomezApplied Metabolomics Research Group, IMIM, Hospital del Mar, Doctor Aiguader 88, 08003 Barcelona, Spain.ORCID 0000-0001-8172-1827
Paula AguileraDiagnosis and Management of Porphyria Clinic, Department of Dermatologyt, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Klaus LangohrIntegrative Pharmacology and Systems Neuroscience Group, IMIM, Hospital del Mar, Doctor Aiguader 88, 08003 Barcelona, Spain.ORCID 0000-0001-7075-9192
Gregori CasalsBiochemistry and Molecular Genetics Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.ORCID 0000-0002-3271-1371
Cristina PavonCerba Internacional, Pl. Ramon Llull 7-10, 08203 Sabadell, Spain.
Josep MarcosDepartment of Medicine and Life Sciences (CEXS-UPF), University Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Spain.
Jordi To-FiguerasBiochemistry and Molecular Genetics Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Oscar J PozoApplied Metabolomics Research Group, IMIM, Hospital del Mar, Doctor Aiguader 88, 08003 Barcelona, Spain.ORCID 0000-0002-1735-9728
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Del Mar · ESUniversitat Pompeu Fabra · ESUniversitat de Barcelona · ES

Funding

Government of Catalonia 2014SGR692Instituto de Salud Carlos III CPII16/00027Instituto de Salud Carlos III PI14/00147
6 · The paper itself

Abstract

Acute intermittent porphyria (AIP) is an inherited rare hepatic disorder due to mutations within the hydroxymethylbilane gene. AIP patients with active disease overproduce aminolevulinic acid (ALA) and porphobilinogen (PBG) in the liver which are exported inducing severe neurological attacks. Different hepatic metabolic abnormalities have been described to be associated with this condition. The goal of this research was to explore the metabolome of symptomatic AIP patients by state-of-the art liquid chromatography-tandem mass spectrometry (LC-MS/MS). A case versus control study including 18 symptomatic AIP patients and 33 healthy controls was performed. Plasmatic levels of 51 metabolites and 16 ratios belonging to four metabolic pathways were determined. The results showed that the AIP patients presented significant changes in the two main areas of the metabolome under study: (a) the tryptophan/kynurenine pathway with an increase of tryptophan in plasma together with increase of the kynurenine/tryptophan ratio; and (b) changes in the tricarboxylic acid cycle (TCA) including increase of succinic acid and decrease of the fumaric acid/succinic acid ratio. We performed a complementary in vitro study adding ALA to hepatocytes media that showed some of the effects on the TCA cycle were parallel to those observed in vivo. Our study confirms in plasma previous results obtained in urine showing that AIP patients present a moderate increase of the kynurenine/tryptophan ratio possibly associated with inflammation. In addition, it also reports changes in the mitochondrial TCA cycle that, despite requiring further research, could be associated with an energy misbalance due to sustained overproduction of heme-precursors in the liver.

Indexed as

Porphyria, Acute IntermittentAminolevulinic AcidChromatography, LiquidHumansKynurenineMetabolomicsSuccinic AcidTandem Mass SpectrometryTryptophanAminolevulinic AcidKynurenineSuccinic AcidTryptophanacute intermittent porphyriakynurenineLC-MS/MSmetabolomicstricarboxylic acid cycletryptophan

Identifiers

PMID35328641
PMCPMC8950560
OpenAlexW4220694707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.